\subsection{Cyclopentanol derivatives}

\subsubsection{Synthesis of the cyclopentanol head groups }

Synthesis of the cyclopentanol derivatives began with the synthesis of (1\textit{S},2\textit{S})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_SS} and (1\textit{R},2\textit{R})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_RR} (see \ref{sch:HOcy5NH2_synth}), using a procedure reported by Overman and Sugai\cite{Aube1992,Overman1985,Overman1985a}.
These precursors were synthesised by opening cyclopentene oxide \compound{cmpd:Ocy5} using (\textit{S})-1-phenylethan-1-amine \compound{cmpd:NH2MeBn} to give approximately equal amounts of two diastereomers, \compound{cmpd:HOcy5NHMeBn_SSS} and \compound{cmpd:HOcy5NHMeBn_RRS}, which were separated using column chromatography. 
The removal of the methylbenzyl groups proved more difficult than expected, with the conditions reported by Overman and Sugai\cite{Overman1985} yielding only a salt of the starting material.
After several attempts under various conditions (including using the free amine vs. the salt, varying the temperature, ensuring the dryness of the reagents and adding acetic acid), an approach using \ce{H2} gas was attempted (see \ref{tbl:HOcy5NH2_opt}). This proceeded smoothly at 5 atm to give the two enantiomers of 2-aminocyclopentan-1-ol, \compound{cmpd:HOcy5NH2_SS} and \compound{cmpd:HOcy5NH2_RR}, both in quantitative yield.

\begin{scheme}[H]
	\begin{center}
		\schemeref[Ocy5]{cmpd:Ocy5}
		\schemeref[NH2MeBn]{cmpd:NH2MeBn}
		\schemeref[HOcy5NHMeBn_RRS]{cmpd:HOcy5NHMeBn_RRS}
		\schemeref[HOcy5NHMeBn_SSS]{cmpd:HOcy5NHMeBn_SSS}
		\schemeref[HOcy5NH2_RR]{cmpd:HOcy5NH2_RR}
		\schemeref[HOcy5NH2_SS]{cmpd:HOcy5NH2_SS}
		\includegraphics[scale=1]{HOcy5NH2_synth}
		\caption{Synthesis of (1\textit{S},2\textit{S})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_SS} and (1\textit{R},2\textit{R})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_RR}
		a) \ce{AlMe3}, \ce{CH2Cl2}, 0 $^\circ$C,  
		\compound{cmpd:HOcy5NHMeBn_SSS} (\textit{SSS}): 35.2 \%,
		\compound{cmpd:HOcy5NHMeBn_RRS} (\textit{RRS}): 32.1 \%.
		b) See \ref{tbl:HOcy5NH2_opt}.
		c) \ce{Pd(OH)2}, MeOH, \ce{H2}, 5 atm, r.t., 1 d, 100 \%.
		\label{sch:HOcy5NH2_synth}}
	\end{center}
\end{scheme}


\renewcommand{\arraystretch}{1.2}
\begin{table}[H]
  \centering
\begin{tabular}{|p{6cm}|p{2.4cm}|l|p{6cm}|}
\hline 
Conditions & Temperature and pressure & Time & Result \\ 
\hline 
\ce{\compound{cmpd:HOcy5NHMeBn_SSS}.HCl}, ammonium formate, 10 \% Pd/C, DMF & r.t., 1 atm & 2 d & \compound{cmpd:HOcy5NHMeBn_SSS} salt \\ %LMO-2-047
\hline 
\compound{cmpd:HOcy5NHMeBn_SSS}, ammonium formate, 10 \% Pd/C, DMF & r.t., 1 atm & 2 d & \compound{cmpd:HOcy5NHMeBn_SSS} salt \\ %LMO-2-048
\hline 
\ce{\compound{cmpd:HOcy5NHMeBn_SSS}.HCl}, ammonium formate, 10 \% Pd/C, dry DMF & r.t., 1 atm & 2 d & \compound{cmpd:HOcy5NHMeBn_SSS} salt \\ %LMO-2-049
\hline 
\compound{cmpd:HOcy5NHMeBn_RRS}, ammonium formate, 10 \% Pd/C, dry DMF & r.t., 1 atm & 2 d & \compound{cmpd:HOcy5NHMeBn_RRS} salt \\ %LMO-2-050
\hline 
\compound{cmpd:HOcy5NHMeBn_SSS}, ammonium formate, 10 \% Pd/C, dry DMF & 70 $^{\circ}$C, 1 atm & 1 d & \compound{cmpd:HOcy5NHMeBn_SSS} salt \\ %LMO-2-051
\hline 
\compound{cmpd:HOcy5NHMeBn_SSS}, ammonium formate, 10 \% Pd/C, dry DMF, AcOH & 70 $^{\circ}$C, 1 atm & 1 d & Complex mixture \\ %LMO-2-051
\hline 
\ce{\compound{cmpd:HOcy5NHMeBn_SSS}.HCl}, dry ammonium formate, 10 \% Pd/C, dry DMF & 120 $^{\circ}$C, 1 atm & 7 d & Complex mixture \\ %LMO-2-054
\hline 
\ce{\compound{cmpd:HOcy5NHMeBn_SSS}.HCl}, \ce{Pd(OH)2}, MeOH, \ce{H2} & r.t., 1 atm & 1 d & \compound{cmpd:HOcy5NHMeBn_SSS} salt \\ %LMO-2-056
\hline 
\ce{\compound{cmpd:HOcy5NHMeBn_SSS}.HCl}, \ce{Pd(OH)2}, MeOH, \ce{H2} & r.t., 3.4 atm & 1 d & \compound{cmpd:HOcy5NH2_SS} salt, \compound{cmpd:HOcy5NHMeBn_SSS} salt, and an unidentified compound (approx. 7:2:10 by $^1$H NMR) \\ %LMO-2-055
\hline 
\compound{cmpd:HOcy5NHMeBn_SSS}, \ce{Pd(OH)2}, MeOH, \ce{H2} & r.t., 5 atm & 1 d & \compound{cmpd:HOcy5NH2_SS}, 100 \% yield \\ %LMO-2-057
\hline 
\end{tabular} 
\caption{Conditions attempted for the synthesis of (1\textit{S},2\textit{S})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_SS} and (1\textit{R},2\textit{R})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_RR} (see \ref{sch:HOcy5NH2_synth}).\label{tbl:HOcy5NH2_opt}} 
\end{table}

\subsubsection{Initial branching strategy}

An initial retrosynthesis of the conjugates is shown in \ref{sch:HOcy5NH4_retro_A}, and follows a similar path to previous conjugates.

Synthesis of Br-C$_4$-cyclopentanol-(\textit{SS}) \compound{cmpd:HOcy5NH4Br_SS} from (1\textit{S},2\textit{S})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_SS} and 4-bromobutyryl chloride \compound{cmpd:Cl4Br} was attempted using Schotten-Baumann conditions (see \ref{sch:HOcy5NH4Br_SS_synth}). However, a large number of impurities were observed by LCMS (see \ref{fig:HOcy5NH4Br_SS_impurities}), and so three new strategies were attempted: protection of the alcohol (see \ref{sec:TBDMS}), installing the linker on methyl ciprofloxacin \compound{cmpd:CipMe} and then attaching the head group by peptide coupling (see \ref{sec:CipMe_linker}), and using 4-chlorobutyryl chloride \compound{cmpd:Cl4Cl} as the linker instead of 4-bromobutyryl chloride \compound{cmpd:Cl4Br} (see \ref{sec:Cl4Cl}).

\begin{scheme}[H]
	\begin{center}
		\schemeref[HOcy5NH2_RR]{cmpd:HOcy5NH2_RR}
		\schemeref[HOcy5NH4Br_RR]{cmpd:HOcy5NH4Br_RR}
		\schemeref[HOcy5NH4N3_RR]{cmpd:HOcy5NH4N3_RR}
		\schemeref[HOcy5NH4CipMe_RR]{cmpd:HOcy5NH4CipMe_RR}
		\schemeref[HOcy5NH4T4Cip_RR]{cmpd:HOcy5NH4T4Cip_RR}
		\schemeref[HOcy5NH2_SS]{cmpd:HOcy5NH2_SS}
		\schemeref[HOcy5NH4Br_SS]{cmpd:HOcy5NH4Br_SS}
		\schemeref[HOcy5NH4N3_SS]{cmpd:HOcy5NH4N3_SS}
		\schemeref[HOcy5NH4CipMe_SS]{cmpd:HOcy5NH4CipMe_SS}
		\schemeref[HOcy5NH4T4Cip_SS]{cmpd:HOcy5NH4T4Cip_SS}
		\includegraphics[scale=1]{HOcy5NH4_retro_A_wedges}
		\caption{Retrosynthesis of the cyclopentanol-CipMe conjugates 
		\compound{cmpd:HOcy5NH4CipMe_SS} (\textit{SS}) and 
		\compound{cmpd:HOcy5NH4CipMe_RR} (\textit{RR}),
		and the cyclopentanol-Cip triazole conjugates 
		\compound{cmpd:HOcy5NH4T4Cip_SS} (\textit{SS}) and  \compound{cmpd:HOcy5NH4T4Cip_RR} (\textit{RR}). 
		\textit{SS} enantiomers are shown, but both will be synthesised. \label{sch:HOcy5NH4_retro_A}}
	\end{center}
\end{scheme}



%LMO-2-058

\begin{scheme}[H]
	\begin{center}
		\schemeref[HOcy5NH2]{cmpd:HOcy5NH2_SS}
		\schemeref[Cl4Br]{cmpd:Cl4Br}
		\schemeref[HOcy5NH4Br]{cmpd:HOcy5NH4Br_SS}
		\includegraphics[scale=1]{HOcy5NH4Br_SS_synth}
		\caption{Synthesis of Br-C$_4$-cyclopentanol-(\textit{SS}) \compound{cmpd:HOcy5NH4Br_SS}.
		a) \ce{NaHCO3}, \ce{CH2Cl2}, \ce{H2O}, 0 $^{\circ}$C, 2 h. \label{sch:HOcy5NH4Br_SS_synth}}
	\end{center}
\end{scheme}

\begin{figure}[H]
	\begin{center}
		\includegraphics[scale=1]{HOcy5NH4Br_SS_impurities}
		\caption{Impurities observed by LCMS during the synthesis of Br-C$_4$-cyclopentanol-(\textit{SS}) \compound{cmpd:HOcy5NH4Br_SS}.
		Regiochemistry is speculative.
		\label{fig:HOcy5NH4Br_SS_impurities}}
	\end{center}
\end{figure}

\subsubsection{TBDMS protection of the alcohol \label{sec:TBDMS}}

\subsubsubsection{Initial protection strategy}

The first attempt at an alternative strategy for the synthesis of the conjugates involved TBDMS protection of the alcohol (see \ref{sch:HOcy5NH4_retro_B}). It was envisaged that protection would eliminate enough of the side reactions with products shown in \ref{fig:HOcy5NH4Br_SS_impurities} that intermediates Br-C$_4$-cyclopentanol-(\textit{SS}) \compound{cmpd:HOcy5NH4Br_SS} and N$_3$-C$_4$-cyclopentanol-(\textit{SS}) \compound{cmpd:HOcy5NH4N3_SS} could be purified. The TBDMS group could be removed later in the synthesis using TBAF or acid.

\begin{scheme}[H]
	\begin{center}
		\schemeref[HOcy5NH2_RR]{cmpd:HOcy5NH2_RR}
		\schemeref[TBSOcy5NH2_RR]{cmpd:TBSOcy5NH2_RR}
		\schemeref[TBSOcy5NH4Br_RR]{cmpd:TBSOcy5NH4Br_RR}
		\schemeref[TBSOcy5NH4N3_RR]{cmpd:TBSOcy5NH4N3_RR}
		\schemeref[TBSOcy5NH4CipMe_RR]{cmpd:TBSOcy5NH4CipMe_RR}
		\schemeref[TBSOcy5NH4T4Cip_RR]{cmpd:TBSOcy5NH4T4Cip_RR}
		\schemeref[HOcy5NH4CipMe_RR]{cmpd:HOcy5NH4CipMe_RR}
		\schemeref[HOcy5NH4T4Cip_RR]{cmpd:HOcy5NH4T4Cip_RR}
		\schemeref[HOcy5NH2_SS]{cmpd:HOcy5NH2_SS}
		\schemeref[TBSOcy5NH2_SS]{cmpd:TBSOcy5NH2_SS}
		\schemeref[TBSOcy5NH4Br_SS]{cmpd:TBSOcy5NH4Br_SS}
		\schemeref[TBSOcy5NH4N3_SS]{cmpd:TBSOcy5NH4N3_SS}
		\schemeref[TBSOcy5NH4CipMe_SS]{cmpd:TBSOcy5NH4CipMe_SS}
		\schemeref[TBSOcy5NH4T4Cip_SS]{cmpd:TBSOcy5NH4T4Cip_SS}
		\schemeref[HOcy5NH4CipMe_SS]{cmpd:HOcy5NH4CipMe_SS}
		\schemeref[HOcy5NH4T4Cip_SS]{cmpd:HOcy5NH4T4Cip_SS}
		\includegraphics[scale=1]{HOcy5NH4_retro_B}
		\caption{Retrosynthesis of the cyclopentanol-CipMe conjugates 
		\compound{cmpd:HOcy5NH4CipMe_SS} (\textit{SS}) and  \compound{cmpd:HOcy5NH4CipMe_RR} (\textit{RR}), 
		and the cyclopentanol-Cip triazole conjugates 
		\compound{cmpd:HOcy5NH4T4Cip_SS} (\textit{SS}) and
		\compound{cmpd:HOcy5NH4T4Cip_RR} (\textit{RR}) 
		using a TBDMS protection strategy. \textit{SS} enantiomers are shown, but both will be synthesised.\label{sch:HOcy5NH4_retro_B}}
	\end{center}
\end{scheme}

The synthesis began with the optimisation of the protection of (1\textit{S},2\textit{S})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_SS} with a TBDMS group on the alcohol (see \ref{sch:TBSOcy5NH4Br_SS_synth}).

Opt.

OTf\cite{Wu2012}
Cl \cite{Robak2007}
DBU \cite{Orsini1989}

\begin{scheme}[H]
	\begin{center}
		\schemeref[HOcy5NH2]{cmpd:HOcy5NH2_SS}
		\schemeref[Cl4Br]{cmpd:Cl4Br}
		\schemeref[TBSOcy5NH2]{cmpd:TBSOcy5NH2_SS}
		\schemeref[TBSOcy5NH4Br]{cmpd:TBSOcy5NH4Br_SS}
		\includegraphics[scale=1]{TBSOcy5NH4Br_SS_synth}
		\caption{The attempted synthesis of Br-C$_4$-cyclopentanol-TBDMS-(\textit{SS}) \compound{cmpd:TBSOcy5NH4Br_SS}. 
		a) See \ref{tbl:TBSOcy5NH4Br_SS_opt}.
		b) \ce{NaHCO3}, \ce{CH2Cl2}, \ce{H2O}, 0 $^{\circ}$C, 2 h. %069,072,073
		\label{sch:TBSOcy5NH4Br_SS_synth}}
	\end{center}
\end{scheme}

\renewcommand{\arraystretch}{1.2}
\begin{table}[H]
  \centering
\begin{tabular}{|p{6cm}|l|l|l|}
\hline 
Conditions & Temperature & Time & Result \\ 
\hline 
TBDMSCl, DMAP, TEA, \ce{CH2Cl2} & r.t. & 18 h & Trace of \compound{cmpd:TBSOcy5NH2_SS}, mostly \compound{cmpd:HOcy5NH2_SS} \\%LMO-2-060, LMO-2-067 
\hline 
TBDMSCl, DMAP, TEA, \ce{CH2Cl2} & r.t. & 1 d & Didn't go to completion, lost on prep TLC  \\ %LMO-2-063
\hline 
TBDMSCl, imidazole, \ce{CH2Cl2} & 0 $^{\circ}$C & 1 h & \compound{cmpd:HOcy5NH2_SS} \\ %LMO-2-064, LMO-2-066
\hline 
TBDMSCl, DBU, MeCN & 0 $^{\circ}$C & 1 d & \compound{cmpd:HOcy5NH2_SS} \\ %LMO-2-065
\hline 
TBDMSOTf, TEA, \ce{CH2Cl2} & 0 $^{\circ}$C & 4 h & \compound{cmpd:TBSOcy5NH2_SS} possibly seen but lost in workup \\ %LMO-2-062
\hline 
TBDMSOTf in 2 portions, TEA, \ce{CH2Cl2}, \ce{NH4Cl} workup & 0 $^{\circ}$C & 6 h & \compound{cmpd:TBSOcy5NH2_SS} salt \\ %LMO-2-068
\hline 
TBDMSOTf in 2 portions, TEA, \ce{CH2Cl2}, aq. workup then column & 0 $^{\circ}$C & 6 h & \compound{cmpd:TBSOcy5NH2_SS}, 85 \% yield \\ %LMO-2-070, LMO-2-071
\hline 
\end{tabular} 
\caption{Conditions attempted for the synthesis of (1\textit{S},2\textit{S})-2-((\textit{tert}-butyldimethylsilyl)oxy)cyclopentan-1-amine \compound{cmpd:TBSOcy5NH2_SS} (see \ref{sch:TBSOcy5NH4Br_SS_synth}).\label{tbl:TBSOcy5NH4Br_SS_opt}} 
\end{table}

Still get side-reactions when adding tail\todo{come back to}

\subsubsubsection{Triazoles by two-step reaction}

Talk about moving to two-step reaction.\todo{come back to}

\begin{scheme}[H]
	\begin{center}
		\schemeref[TBSOcy5NH2]{cmpd:TBSOcy5NH2_SS}
		\schemeref[Cl4Br]{cmpd:Cl4Br}
		\schemeref[TBSOcy5NH4Br]{cmpd:TBSOcy5NH4Br_SS}		\schemeref[TBSOcy5NH4N3]{cmpd:TBSOcy5NH4N3_SS}
		\includegraphics[scale=1]{TBSOcy5NH4N3_SS_synth_2step}
		\caption{
		a) \ce{NaHCO3}, \ce{CH2Cl2}, \ce{H2O}, 0 $^{\circ}$C, 3 h.
		b) \ce{NaN3}, DMF, \ce{CH2Cl2}, r.t., 3 h. 
		99.2 \% over 2 steps. %LMO-2-078
		\label{sch:TBSOcy5NH4N3_SS_synth_2step}}
	\end{center}
\end{scheme}

N$_3$-C$_4$-cyclopentanol-TBDMS-(\textit{SS}) \compound{cmpd:TBSOcy5NH4N3_SS} and the alkynyl ciprofloxacin derivative \compound{cmpd:Y4Cip} were subjected to standard click conditions, and the TBDMS-protected (\textit{SS})-cyclopentanol-Cip triazole conjugate \compound{cmpd:TBSOcy5NH4T4Cip_SS} was synthesised in very good yield. However, removal of the TBDMS group proved difficult. Deprotection using 1.5 eq. TBAF in THF proceeded slowly, reaching completion in 5 d. Increasing the amount of TBAF to 8 eq. allowed the reaction to proceed overnight.
Purification of the final conjugate \compound{cmpd:HOcy5NH4T4Cip_SS} by column chromatography was not successful due to streaking and poor separation. Purification using DOWEX resin and \ce{CaCO3} was attempted, but the product could not be recovered from the resin.
The purification method could probably be optimised, e.g. by varying the solvent used with the resin, but ultimately this route was abandoned due to the reduction in number of steps afforded by the two methods described below.

\begin{scheme}[H]
	\begin{center}
		\schemeref[TBSOcy5NH4N3]{cmpd:TBSOcy5NH4N3_SS}
		\schemeref[Y4Cip]{cmpd:Y4Cip}
		\schemeref[TBSOcy5NH4T4Cip]{cmpd:TBSOcy5NH4T4Cip_SS}
		\schemeref[HOcy5NH4T4Cip]{cmpd:HOcy5NH4T4Cip_SS}
		\includegraphics[scale=1]{TBSOcy5NH4T4Cip_SS_synth}
		\caption{
		a) \ce{CuSO4}, sodium ascorbate, THPTA, \ce{H2O}, \textit{t}-BuOH, r.t., 87.4 \%. %, LMO-2-082
		b) TBAF, THF, r.t., 16 h. %LMO-2-084, 090, Lost on purification
		\label{sch:TBSOcy5NH4T4Cip_SS_synth}}
	\end{center}
\end{scheme}

\subsubsection{Peptide coupling route\label{sec:CipMe_linker}}

Given the side-reactions and low yields associated with the literate synthesis of the S$_N$2 conjugates proposed by Ganguly et. al\cite{Ganguly2011}, an alternative synthesis was investigated, involving building up the linker on the ciprofloxacin side before coupling with the head group (see \ref{sch:HOcy5NH4_retro_D}).

%This was tested with _RR

\begin{scheme}[H]
	\begin{center}
		\schemeref[HOcy5NH2_SS]{cmpd:HOcy5NH2_SS}
		\schemeref[HOcy5NH2_RR]{cmpd:HOcy5NH2_RR}
		\schemeref[HOO4CipMe]{cmpd:HOO4CipMe}
		\schemeref[tBuOO4CipMe]{cmpd:tBuOO4CipMe}
		\schemeref[tBuOO4Br]{cmpd:tBuOO4Br}
		\schemeref[CipMe]{cmpd:CipMe}
		\schemeref[HOcy5NH4CipMe_SS]{cmpd:HOcy5NH4CipMe_SS}
		\schemeref[HOcy5NH4CipMe_RR]{cmpd:HOcy5NH4CipMe_RR}
		\includegraphics[scale=1]{HOcy5NH4_retro_D}
		\caption{Retrosynthesis of the cyclopentanol-CipMe conjugates  \compound{cmpd:HOcy5NH4CipMe_SS} (\textit{SS}) and \compound{cmpd:HOcy5NH4CipMe_RR} (\textit{RR}). \textit{SS} enantiomers are shown, but both will be synthesised.\label{sch:HOcy5NH4_retro_D}}
	\end{center}
\end{scheme}

%a
The first step of the synthesis was an S$_N$2 reaction between Boc-protected 4-bromobutyric acid \compound{cmpd:tBuOO4Br} methyl ciprofloxacin \compound{cmpd:CipMe} (see \ref{sch:HOcy5NH4CipMe_RR_synth}). This reaction used fairly harsh conditions (16 h at 100 $^{\circ}$C), but early on in the synthesis before the head group was installed. Hence the possibility of side reactions between the bromide and the amine was removed. Intermediate \compound{cmpd:tBuOO4CipMe} was obtained in acceptable yield after column chromatography (49.9 \%).
%b
Intermediate \compound{cmpd:tBuOO4CipMe} was deprotected in excellent yield using TFA in \ce{CH2Cl2} to give carboxylic acid \compound{cmpd:HOO4CipMe}. Scale-up of this reaction allowed the easy synthesis of 600 mg of this useful intermediate, which can be coupled with various amine head-groups to create a library.
%c
Carboxylic acid \compound{cmpd:HOO4CipMe} was first coupled with (1\textit{R},2\textit{R})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_RR} using standard peptide coupling conditions to give cyclopentanol-CipMe conjugate \compound{cmpd:HOcy5NH4CipMe_RR}. Purification by column chromatography was attempted twice with poor results, before moving on to using preparative HPLC, which gave \compound{cmpd:HOcy5NH4CipMe_RR} cleanly in 38.7 \% yield.
Coupling was also performed with (1\textit{S},2\textit{S})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_SS} to give the enantiomer \compound{cmpd:HOcy5NH4CipMe_SS} in 54.7 \% yield.

Direct comparisons of routes are not possible without repeating syntheses using this new method, but if it is assumed that peptide coupling of homocysteine thiolactone hydrochloride \compound{cmpd:SHLHCl} to carboxylic acid \compound{cmpd:HOO4CipMe} would have a similar yield to the coupling with (1\textit{R},2\textit{R})-2-aminocyclopentan-1-ol \compound{cmpd:HOcy5NH2_RR}, approximate comparisons can be made.
The synthesis described in \ref{sec:HCTL} has an overall yield of 10.7 \%, whereas the route shown in \ref{sch:HOcy5NH4CipMe_RR_synth} for \compound{cmpd:HOcy5NH4CipMe_SS} has an overall yield of 26.1 \%. Moreover, if the yield starting from the head group (which may be expensive, difficult to synthesise and/or unstable) is considered, the yield is 54.7 \% vs. 10.7 \%.
Therefore, this route is recommended for further investigation if the library is to be expanded.

A downside to this route is that it cannot branch towards the triazole-coupled library in the same way that the route in \ref{sec:HCTL}. A carboxylic acid intermediate with a triazole in the chain could presumably be synthesised, but this would be rather pointless given that the triazole library was initially proposed so that the two sides could be joined by the 'click' reaction.
Therefore, an alternative route to the azide was proposed, via a more stable chloride intermediate (see \ref{sec:Cl4Cl}).

%From head
%87.9*12.2=10.7
%38.7
%longest route
%87.9*12.2=10.7
%49.9*95.6*54.7=26.1

\begin{scheme}[H]
	\begin{center}
		\schemeref[CipMe]{cmpd:CipMe}
		\schemeref[tBuOO4Br]{cmpd:tBuOO4Br}
		\schemeref[tBuOO4CipMe]{cmpd:tBuOO4CipMe}
		\schemeref[HOO4CipMe]{cmpd:HOO4CipMeTFA}
		\schemeref[HOcy5NH2_SS]{cmpd:HOcy5NH2_SS}
		\schemeref[HOcy5NH2_RR]{cmpd:HOcy5NH2_RR}
		\schemeref[HOcy5NH4CipMe_SS]{cmpd:HOcy5NH4CipMe_SS}
		\schemeref[HOcy5NH4CipMe_RR]{cmpd:HOcy5NH4CipMe_RR}
		\includegraphics[scale=1]{HOcy5NH4CipMe_RR_synth}
		\caption{Synthesis of the cyclopentanol-CipMe conjugates  \compound{cmpd:HOcy5NH4CipMe_SS} (\textit{SS}) and \compound{cmpd:HOcy5NH4CipMe_RR} (\textit{RR}) by peptide coupling. 
		\textit{SS} enantiomers are shown, but both were synthesised.
			a) NaI, TEA, acetonitrile, 100 $^{\circ}$C, 16 h, 49.9 \%. %, LMO-2-081
			b) TFA,  \ce{CH2Cl2}, r.t., 18 h, 95.6 \%. %, LMO-2-083. 
			c) EDC, HOBt, DIPEA, DMF, r.t., 16 h, 
			\compound{cmpd:HOcy5NH4CipMe_SS} (\textit{SS}): 54.7 \%,  %LMO-3-019
			\compound{cmpd:HOcy5NH4CipMe_RR} (\textit{RR}): 38.7 \%. %LMO-2-093
			\label{sch:HOcy5NH4CipMe_RR_synth}}
	\end{center}
\end{scheme}



\subsubsection{Triazoles from chlorides\label{sec:Cl4Cl}}

A final attempt at a branching strategy was attempted, via a chloride rather than a bromide intermediate (see \ref{sch:HOcy5NH4_retro_C} and \ref{sch:HOcy5NH4_retro_A} for comparison). The bromide intermediate was initially chosen as it was used by Ganguly et. al\cite{Ganguly2011}, but it was hoped that using a chloride would cut out some of the side reactions seen with the more reactive bromide.

\begin{scheme}[H]
	\begin{center}
		\schemeref[HOcy5NH2_SS]{cmpd:HOcy5NH2_SS}
		\schemeref[HOcy5NH4Cl_SS]{cmpd:HOcy5NH4Cl_SS}
		\schemeref[HOcy5NH4N3_SS]{cmpd:HOcy5NH4N3_SS}
		\schemeref[HOcy5NH4CipMe_SS]{cmpd:HOcy5NH4CipMe_SS}
		\schemeref[HOcy5NH4T4Cip_SS]{cmpd:HOcy5NH4T4Cip_SS}
		\schemeref[HOcy5NH2_RR]{cmpd:HOcy5NH2_RR}
		\schemeref[HOcy5NH4Cl_RR]{cmpd:HOcy5NH4Cl_RR}
		\schemeref[HOcy5NH4N3_RR]{cmpd:HOcy5NH4N3_RR}
		\schemeref[HOcy5NH4CipMe_RR]{cmpd:HOcy5NH4CipMe_RR}
		\schemeref[HOcy5NH4T4Cip_RR]{cmpd:HOcy5NH4T4Cip_RR}
		\includegraphics[scale=1]{HOcy5NH4_retro_C}
		\caption{Retrosynthesis of the cyclopentanol-CipMe conjugates 
		\compound{cmpd:HOcy5NH4CipMe_SS} (\textit{SS}) and
		\compound{cmpd:HOcy5NH4CipMe_RR} (\textit{RR}), 
		and the cyclopentanol-Cip triazole conjugates 
		\compound{cmpd:HOcy5NH4T4Cip_SS} (\textit{SS}) and
		\compound{cmpd:HOcy5NH4T4Cip_RR} (\textit{RR})  
		via Cl-C$_4$-cyclopentanol intermediates 
		\compound{cmpd:HOcy5NH4Cl_SS} (\textit{SS}) and 
		\compound{cmpd:HOcy5NH4Cl_RR} (\textit{RR}). 
		\textit{SS} enantiomers are shown, but both will be synthesised.
		\label{sch:HOcy5NH4_retro_C}}
	\end{center}
\end{scheme}

Attempts at this route began with the synthesis of Cl-C$_4$-cyclopentanol-(\textit{RR}) \compound{cmpd:HOcy5NH4Cl_RR}. Standard Schotten-Baumann conditions failed to produce significant amounts of product, due to degradation of the acid chloride to the carboxylic acid. \todo{I can't think of a good reason why this happened to the tail chloride and not the bromide.}
Therefore, new conditions were attempted using just \ce{CH2Cl2} as the solvent and TEA as the base. This produced Cl-C$_4$-cyclopentanol-(\textit{RR}) \compound{cmpd:HOcy5NH4Cl_RR} in good yield (64.1 \%), which appeared to be stable when concentrated unlike the bromide \compound{cmpd:HOcy5NH4Br_SS}.



%Cl
%Mass Solubility	Slightly Soluble (7.8 g/L)	Unbuffered Water pH 7.00 Temp: 25 °C
%logP	1.283±0.420	Temp: 25 °C
%Br
%Mass Solubility	Slightly Soluble (7.0 g/L)	Unbuffered Water pH 7.00 Temp: 25 °C
%logP	1.487±0.410	Temp: 25 °C
%
%Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2018 ACD/Labs)

\begin{scheme}[H]
	\begin{center}
		\schemeref[HOcy5NH2_SS]{cmpd:HOcy5NH2_SS}
		\schemeref[Cl4Cl]{cmpd:Cl4Cl}
		\schemeref[HOcy5NH4Cl_SS]{cmpd:HOcy5NH4Cl_SS}
		\schemeref[HOcy5NH4N3_SS]{cmpd:HOcy5NH4N3_SS}
		\schemeref[HOcy5NH2_RR]{cmpd:HOcy5NH2_RR}
		\schemeref[HOcy5NH4Cl_RR]{cmpd:HOcy5NH4Cl_RR}
		\schemeref[HOcy5NH4N3_RR]{cmpd:HOcy5NH4N3_RR}
		\includegraphics[scale=1]{HOcy5NH4N3_synth}
		\caption{Synthesis of N$_3$-C$_4$-cyclopentanol-(\textit{SS}) \compound{cmpd:HOcy5NH4N3_SS} and N$_3$-C$_4$-cyclopentanol-(\textit{RR}) \compound{cmpd:HOcy5NH4N3_RR}. 
		\textit{SS} enantiomers are shown, but both were synthesised.
		a) TEA, \ce{CH2Cl2}, 0 $^{\circ}$C, 2 h,
		\compound{cmpd:HOcy5NH4Cl_SS} (\textit{SS}): 24.2 \%, 
		\compound{cmpd:HOcy5NH4Cl_RR} (\textit{RR}): 64.1 \%.
		b) \ce{NaN3}, acetonitrile, 50 $^\circ$C, 24 h, 
		\compound{cmpd:HOcy5NH4N3_SS} (\textit{SS}): 45.0 \%, 
		\compound{cmpd:HOcy5NH4N3_RR} (\textit{RR}): 87.6 \%.
		\label{sch:HOcy5NH4N3_synth}}
	\end{center}
\end{scheme}

\begin{scheme}[H]
	\begin{center}
		\schemeref[HOcy5NH4N3_SS]{cmpd:HOcy5NH4N3_SS}
		\schemeref[Y4Cip]{cmpd:Y4Cip}
		\schemeref[HOcy5NH4T4Cip_SS]{cmpd:HOcy5NH4T4Cip_SS}
		\schemeref[HOcy5NH4N3_RR]{cmpd:HOcy5NH4N3_RR}
		\schemeref[HOcy5NH4T4Cip_RR]{cmpd:HOcy5NH4T4Cip_RR}
		\includegraphics[scale=1]{HOcy5NH4T4Cip_synth}
		\caption{Synthesis of the cyclopentanol-Cip triazole conjugates \compound{cmpd:HOcy5NH4T4Cip_SS} (\textit{SS}) and 
		\compound{cmpd:HOcy5NH4T4Cip_RR} (\textit{RR}). 
		\textit{SS} enantiomers are shown, but both were synthesised.
		a) \ce{CuSO4}, THPTA, sodium ascorbate, \ce{H2O}, \textit{t}-BuOH, \ce{CH2Cl2}, r.t., 3 d, 
		\compound{cmpd:HOcy5NH4T4Cip_SS} (\textit{SS}): 22.2 \%,
		\compound{cmpd:HOcy5NH4T4Cip_RR} (\textit{RR}): 27.1 \%. 
		\label{sch:HOcy5NH4T4Cip_synth}}
	\end{center}
\end{scheme}

This worked.
Mention Sn2 attempt
